Editas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary

Editas Medicine

10/08/2026 12:59

Editas Medicine, Inc. EDIT.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -63 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -32 cents to -22 cents per share.
Revenue rose 232.3% to $11.89 million from a year ago; analysts expected $2.80 million. 
Editas Medicine, Inc.'s reported EPS for the quarter was a loss of 15 cents​.
The company reported a quarterly loss of $18.23 million.
Editas Medicine, Inc. shares had fallen by 11.1% this quarter and gained 40.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Editas Medicine, Inc. is $5.00, about 42.4% above its last closing price of $2.88
This summary was machine generated from LSEG data August 10 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.27
-0.15
Beat
Mar. 31 2026 
-0.26
-0.26
Met
Dec. 31 2025 
-0.26
-0.06
Beat
Sep. 30 2025 
-0.30
-0.28
Beat